alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                    EXHIBIT 31.1

CHIEF EXECUTIVE OFFICER'S CERTIFICATION REQUIRED UNDER SECTION 302 OF
SARBANES-OXLEY ACT OF 2002

I, Edward V. Lett, President and CEO, certify that:

1. I have reviewed this quarterly report on Form 10-Q of TIB Financial Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused, such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant's internal control
over financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially
affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.



Date:   August 8, 2003


                        /s/Edward V. Lett
                        _______________________________
                                Edward V. Lett,
                     President and Chief Executive Officer
# C_2022076EN.01000101.xml

| 17.2.2022 | EN | Official Journal of the European Union | C 76/1 |
| --- | --- | --- | --- |

17.2.2022

EN

Official Journal of the European Union

C 76/1

---

Non-opposition to a notified concentration

(Case M.10617 – EDF / SOJITZ CORPORATION / NEBRAS POWER / KYUDEN INTERNATIONAL CORPORATION / JV)

(Text with EEA relevance)

(2022/C 76/01)

On 07 February 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10617. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10617. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
# C_2022379EN.01001101.xml

| 3.10.2022 | EN | Official Journal of the European Union | C 379/11 |
| --- | --- | --- | --- |

3.10.2022

EN

Official Journal of the European Union

C 379/11

---

Notice of the impending expiry of certain anti-dumping measures

(2022/C 379/06)

1.

As provided for in Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council of 8 June 2016 on protection against dumped imports from countries not members of the European Union (1), the Commission gives notice that, unless a review is initiated in accordance with the following procedure, the anti-dumping measures mentioned below will expire on the date mentioned in the table below.

2.   Procedure

Procedure

Union producers may submit a written request for a review. This request must contain sufficient evidence that the expiry of the measures would be likely to result in a continuation or recurrence of dumping and injury. Should the Commission decide to review the measures concerned, importers, exporters, representatives of the exporting country and Union producers will then be provided with the opportunity to amplify, rebut or comment on the matters set out in the review request.

3.   Time limit

Time limit

Union producers may submit a written request for a review on the above basis, to reach the European Commission, Directorate-General for Trade (Unit G-1), CHAR 4/39, 1049 Brussels, Belgium (2) at any time from the date of the publication of the present notice but no later than three months before the date mentioned in the table below.

2

| 4. | This notice is published in accordance with Article 11(2) of Regulation (EU) 2016/1036.









  Product | Country(ies) of origin or exportation | Measures | Reference | Date of expiry (3) |
| --- | --- | --- | --- | --- | --- |
| Oxalic acid | India
  The People’s Republic of China | Anti-dumping duty | Commission Implementing Regulation (EU) 2018/931 of 28 June 2018 imposing a definitive anti-dumping duty on imports of oxalic acid originating in India and the People’s Republic of China following an expiry review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council
  (OJ L 165, 2.7.2018, p. 13) | 3.7.2023 |

4.

This notice is published in accordance with Article 11(2) of Regulation (EU) 2016/1036.

Product

Country(ies) of origin or exportation

Measures

Reference

Date of expiry (3)

3

Oxalic acid

India

The People’s Republic of China

Anti-dumping duty

Commission Implementing Regulation (EU) 2018/931 of 28 June 2018 imposing a definitive anti-dumping duty on imports of oxalic acid originating in India and the People’s Republic of China following an expiry review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council

(OJ L 165, 2.7.2018, p. 13)

3.7.2023

---

(1)  OJ L 176, 30.6.2016, p. 21.

1

(2)  TRADE-Defence-Complaints@ec.europa.eu

2

(3)  The measure expires at midnight (00:00) of the day mentioned in this column.

3

---
Presidential Documents

Federal Register / Vol. 89, No. 181 / Wednesday, September 18, 2024 / Presidential Documents 76397 

Presidential Determination No. 2024–11 of September 13, 2024 

Continuation of the Exercise of Certain Authorities Under the 

Trading With the Enemy Act 

Memorandum for the Secretary of State [and] the Secretary of the Treasury 

Under section 101(b) of Public Law 95–223 (91 Stat. 1625; 50 U.S.C. 4305 

note), and a previous determination on September 13, 2023 (88 FR 64347, 

September 18, 2023), the exercise of certain authorities under the Trading 

With the Enemy Act is scheduled to expire on September 14, 2024. 

I hereby determine that the continuation of the exercise of those authorities 

with respect to Cuba for 1 year is in the national interest of the United 

States. 

Therefore, consistent with the authority vested in me by section 101(b) 

of Public Law 95–223, I continue for 1 year, until September 14, 2025, 

the exercise of those authorities with respect to Cuba, as implemented by 

the Cuban Assets Control Regulations, 31 CFR part 515. 

The Secretary of the Treasury is authorized and directed to publish this 

determination in the Federal Register. 

THE WHITE HOUSE, 

Washington, September 13, 2024 

[FR Doc. 2024–21450 

Filed 9–17–24; 8:45 am] 

Billing code 4811–33–P 


khammond on DSKJM1Z7X2PROD with PRESDOC4BIDEN.EPS</GPH>
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 16

- 50275 Conference Calendar

UNITED STATES OF AMERICA,

Plaintiff

- Appellee

v.
ERNESTO CALDERON

- SILVERA , Defendant

- Appellant

Appeal from the United States District Court for the Western District of Texas USDC No. 2:12

- CR

- 1630

- 1

Before DENNIS, PRADO, and OWEN, Circuit Judges. PER CURIAM: *
The Federal Public Defender appointed to represent Ernesto Calderon

Silvera has moved for leave to withdraw and has filed a brief in accordance
with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Calderon

- Silvera h a s not fi led a response. We have reviewed counsel’s brief and the relevant portions of the record reflected therein. We concur with counsel’s assessment that the appeal presents no

* Pursuant to 5 TH C IR

. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED December 20 , 2016 Lyle W. Cayce Clerk Case: 16-50275 Document: 00513804385 Page: 1 Date Filed: 12/20/2016No. 16

- 50275

2 nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. See 5 TH C IR

. R. 42.2. Case: 16-50275 Document: 00513804385 Page: 2 Date Filed: 12/20/2016
[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76880]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21314]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail and USPS Ground Advantage[supreg] 
Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: September 19, 2024.

FOR FURTHER INFORMATION CONTACT: Sean Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
September 3, 2024, it filed with the Postal Regulatory Commission a 
USPS Request to Add Priority Mail & USPS Ground Advantage[supreg] 
Contract 327 to Competitive Product List. Documents are available at 
www.prc.gov, Docket Nos. MC2024-608, CP2024-616.

Sean Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2024-21314 Filed 9-18-24; 8:45 am]
BILLING CODE 7710-12-P
| **CONSOLIDATED CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) - $ / shares** | 3 Months Ended | 6 Months Ended |
|-------------------------------------------------------------------------------------------------------|----------------|----------------|
||
| **Statement of Stockholders' Equity [Abstract]**                                                      |           |           |   |   |
| Cash dividends on common stock (in dollars per share)                                                 | $ 0.14         | $ 0.11         | $ 0.25 | $ 0.19 |

| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Aggregate dividends paid during the period for each share of common stock outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details**Name:**us-gaap_CommonStockDividendsPerShareCashPaid**Namespace Prefix:**us-gaap_**Data Type:**num:perShareItemType**Balance Type:**na**Period Type:**duration |
| X                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - References
No definition available.
+ Details**Name:**us-gaap_StatementOfStockholdersEquityAbstract**Namespace Prefix:**us-gaap_**Data Type:**xbrli:stringItemType**Balance Type:**na**Period Type:**duration |
Michigan Supreme Court Lansing, Michigan

Marilyn Kelly,
Chief Justice

Michael F. Cavanag h

Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,

J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk April 8, 2009

s0401 

# Order

April 8, 2009

136514

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee,

v SC: 136514 COA: 280262 Leelanau CC: 06-001498-FC FAYE ROBYN O’NON, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the April 4, 2008 order of the Court of Appeals is considered and, pursuant to MCR 7.302(G)(1), in lieu of granting leave to appeal, we REMAND th is case to the Court of Appeals for consideration, as on leave granted, of the i ssues: (1) whether the redacted transcript of the prior testimony of Matthew O’Non at his own trial, whic h was admitted in this case,

was “testimonial” under Crawford v Washington , 541 US 36; 124 S Ct 1354; 158 L Ed 2d 177 (2004); (2) whether any statements in that transcript were hearsay under MRE 801(c) because they were offe red to prove the truth of the matters asserted and therefore were barred by Crawford ; and (3) whether all statements in that transcript that were offered to prove the falsity of the matters asserted necessarily were not hearsay under MRE 801(c) and thus were not barred by Crawford . In all other respec ts, leave to appeal is DENIED, because we are not persuaded that the remaining questi ons presented should be reviewed by this Court.

We do not retain jurisdiction.
[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76889]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21342]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail Express, Priority Mail, and USPS 
Ground Advantage[supreg] Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: September 19, 2024.

FOR FURTHER INFORMATION CONTACT: Sean C. Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
September 9, 2024, it filed with the Postal Regulatory Commission a 
USPS Request to Add Priority Mail Express, Priority Mail & USPS Ground 
Advantage[supreg] Contract 314 to Competitive Product List. Documents 
are available at www.prc.gov, Docket Nos. MC2024-647, CP2024-656.

Sean C. Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2024-21342 Filed 9-18-24; 8:45 am]
BILLING CODE 7710-12-P
<PAGE>

                                  EXHIBIT 3.1

                           CERTIFICATE OF AMENDMENT OF
                              AMENDED AND RESTATED
                          CERTIFICATE OF INCORPORATION
                                       OF
                           MAXIM PHARMACEUTICALS, INC.

         MAXIM PHARMACEUTICALS, INC., a corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware, hereby
certifies as follows:

         1.       The name of the corporation is Maxim Pharmaceuticals, Inc.

         2.       Maxim Pharmaceuticals, Inc. was originally incorporated on
September 24, 1954, under the name "Wilco Oil & Minerals, Corp."

         3.       This Certificate of Amendment amends certain provisions of the
Amended and Restated Certificate of Incorporation of the corporation and has
been duly adopted by the Board of Directors in accordance with the provisions of
Sections 141 and 242 of the General Corporation Law of the State of Delaware and
by the stockholders of the corporation in accordance with Section 242 of the
General Corporation Law of the State of Delaware.

         4.       Paragraph A of Article IV shall be amended to read in its
entirety as follows:

                  "A. This corporation is authorized to issue two classes of
                  stock to be designated, respectively, "Common Stock" and
                  "Preferred Stock." The total number of shares of all classes
                  of stock which the corporation shall have authority to issue
                  is Forty-Five Million (45,000,000) shares consisting of (a)
                  Forty Million (40,000,000) shares of Common Stock, each having
                  a par value of one tenth of one cent ($.001) and (b) Five
                  Million (5,000,000) shares of Preferred Stock, each having a
                  par value of one tenth of one cent ($0.001)."

                  IN WITNESS WHEREOF, Maxim Pharmaceuticals, Inc. has caused
this Certificate of Amendment to be signed by its President this 29th day of
February, 2000.

                                   MAXIM PHARMACEUTICALS, INC.

                                   By:    /s/ LARRY G. STAMBAUGH
                                          -------------------------------------
                                          Larry G. Stambaugh,
                                          President and Chief Executive Officer

Attest:

By:    /s/ DALE A. SANDER
       --------------------------
       Dale A. Sander,
       Secretary
##### 



ARTICLES OF AMENDMENT
TO
RESTATED ARTICLES OF INCORPORATION
OF
TIB FINANCIAL CORP. Pursuant to Section 607.1006, Florida Statutes, the Restated Articles of Incorporation of TIB
Financial Corp. are hereby amended as follows: FIRST: Article V of the Restated Articles of Incorporation is hereby amended by deleting the
text of such provision in its entirety and insert in lieu thereof the following: ARTICLE V Directors The number of Directors of the Corporation shall be the number from time to time fixed in
accordance with the provisions of the bylaws of the Corporation, but at no time shall the number of
Directors be less than five. The Board of Directors of the Corporation shall be divided into two
classes as equal in number as may be feasible, with the term of office of one class expiring each
year. At each annual meeting of shareholders, successors to the Directors whose terms shall then
expire shall be elected to hold office for terms expiring at the second succeeding annual meeting.
Directors shall continue in office until the end of their respective term and until his or her
successor is elected and qualified or until there is a decrease in the number of Directors.
Whenever a vacancy occurs on the Board of Directors, including a vacancy resulting from an increase
in the number of Directors or otherwise, it shall be filled by the affirmative vote of a majority
of the remaining Directors, though less than a quorum of the Board of Directors, and each
additional Director shall hold office until the next annual meeting of shareholders and until his
or her successor shall have been elected and qualified. When the number of Directors is changed,
any newly created directorships or any decrease in directorships shall be so assigned among the
classes by a majority of the Directors then in office, though less than a quorum, as to make all
classes as equal in number as may be feasible. No decrease in the number of Directors shall shorten
the term of an incumbent Director. IN WITNESS WHEREOF, the undersigned has caused these Articles of Amendment to be executed and
attested to by its duly authorized officer as of this 26th day of April, 2005. TIB FINANCIAL CORP.By:
    /s/ Edward V. LettEdward V. LettPresident and Chief Operating Officer 21




---



##### 



STATE OF FLORIDA
COUNTY OF COLLIER The foregoing instrument was acknowledged before me this 26th day of April, 2005,
by Edward V. Lett as President and Chief Executive Officer of TIB Financial Corp., on behalf of the
Corporation. /s/ John P. Greeley
Printed Name: John P Greely
Notary Public, State of Florida Personally Known þ or Produced Identification o
Type of Identification Produced 22